Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchStudy completedNCT04130152
What this trial is testing

Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 22
Testing effectiveness (Phase 2)Looking for participantsNCT05638594
What this trial is testing

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Who this might be right for
Breast Cancer
Shengjing Hospital 236
Not applicableNot Yet RecruitingNCT07701070
What this trial is testing

SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC

Who this might be right for
Advanced Breast Cancer
AstraZeneca 3,000
Testing effectiveness (Phase 2)Study completedNCT04596150
What this trial is testing

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Neoplasms, Triple-Negative+2 more
CytomX Therapeutics 125
Early research (Phase 1)Looking for participantsNCT05969041
What this trial is testing

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Who this might be right for
Epithelial Tumors, Malignant
Myeloid Therapeutics 48
Testing effectiveness (Phase 2)Looking for participantsNCT04348747
What this trial is testing

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute 23
Early research (Phase 1)Looking for participantsNCT07318805
What this trial is testing

Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)Colorectal Cancer+2 more
Pfizer 260
Testing effectiveness (Phase 2)Looking for participantsNCT06495515
What this trial is testing

Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer

Who this might be right for
CANCERBRAEST CANCERLate Frontline
Tianjin Medical University Cancer Institute and Hospital 36
Not applicableStudy completedNCT05153135
What this trial is testing

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 4,320
Large-scale testing (Phase 3)Looking for participantsNCT06982521
What this trial is testing

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Who this might be right for
PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more
Relay Therapeutics, Inc. 540
Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06404463
What this trial is testing

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Who this might be right for
Early Breast CancerNeoadjuvant TherapyHR+HER2- Breast Cancer
Fudan University 76
Testing effectiveness (Phase 2)Ended earlyNCT04720664
What this trial is testing

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHormone Receptor Positive Breast Carcinoma
Georgetown University 11
Early research (Phase 1)Looking for participantsNCT06562192
What this trial is testing

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast Cancer+2 more
Novartis Pharmaceuticals 162
Large-scale testing (Phase 3)Looking for participantsNCT07467330
What this trial is testing

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment

Who this might be right for
Breast Cancer
Fujian Cancer Hospital 258
Large-scale testing (Phase 3)Active Not RecruitingNCT04851613
What this trial is testing

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Laekna Limited 256
Large-scale testing (Phase 3)Active Not RecruitingNCT05077449
What this trial is testing

XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 300
Testing effectiveness (Phase 2)Looking for participantsNCT07227233
What this trial is testing

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Who this might be right for
Breast Cancer
University of California, San Diego 105
Testing effectiveness (Phase 2)UnknownNCT04941885
What this trial is testing

Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-sen University 78
Testing effectiveness (Phase 2)UnknownNCT05025735
What this trial is testing

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2-negative Breast Cancer
Saint Luke's Health System 25
Next Page